Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | FBRX |
---|---|---|
09:32 ET | 636 | 0.571 |
09:45 ET | 100 | 0.535101 |
09:50 ET | 1427 | 0.55 |
11:00 ET | 300 | 0.53 |
11:36 ET | 358 | 0.54 |
11:54 ET | 922 | 0.5279 |
11:58 ET | 2013 | 0.5299 |
12:02 ET | 4067 | 0.53 |
12:05 ET | 600 | 0.54 |
12:14 ET | 100 | 0.5399 |
12:27 ET | 200 | 0.5299 |
01:08 ET | 662 | 0.53 |
01:12 ET | 800 | 0.52001 |
01:51 ET | 141 | 0.52 |
02:02 ET | 193 | 0.53045 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Forte Biosciences Inc | 20.4M | -0.5x | --- |
Vincerx Pharma Inc | 20.1M | -0.4x | --- |
Indaptus Therapeutics Inc | 21.1M | -1.4x | --- |
Bullfrog AI Holdings, Inc. | 19.6M | -2.7x | --- |
Eom Pharmaceutical Holdings Inc | 21.5M | -4.4x | --- |
Iterum Therapeutics PLC | 19.0M | -0.4x | --- |
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.09 |
EPS | $-1.03 |
Book Value | $0.97 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.